Knight Therapeutics Inc.
TSX:GUD.TO
5.15 (CAD) • At close November 14, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) CAD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 328.199 | 293.563 | 243.478 | 199.519 | 47.461 | 12.5 | 8.634 | 5.94 | 1.037 | 0.365 | 0 |
| Cost of Revenue
| 175.547 | 155.502 | 128.066 | 117.829 | 20.543 | 2.305 | 1.585 | 1.55 | 0.428 | 0 | 0 |
| Gross Profit
| 152.652 | 138.061 | 115.412 | 81.69 | 26.918 | 10.195 | 7.049 | 4.39 | 0.609 | 0.365 | 0 |
| Gross Profit Ratio
| 0.465 | 0.47 | 0.474 | 0.409 | 0.567 | 0.816 | 0.816 | 0.739 | 0.587 | 1 | 0 |
| Reseach & Development Expenses
| 17.549 | 14.755 | 12.692 | 11.725 | 3.913 | 1.991 | 2.75 | 1.955 | 2.707 | 1.029 | 0 |
| General & Administrative Expenses
| 37.414 | 40.15 | 37.159 | 38.845 | 24.46 | 8.467 | 8.198 | 9.302 | 9.086 | 4.283 | 0 |
| Selling & Marketing Expenses
| 46.279 | 48.474 | 37.217 | 35.585 | 7.789 | 3.588 | 3.378 | 0.532 | 0 | 0 | 0 |
| SG&A
| 83.693 | 88.624 | 74.376 | 74.43 | 32.249 | 12.055 | 11.576 | 9.834 | 9.086 | 4.283 | 0 |
| Other Expenses
| 54.3 | 51.742 | 41.176 | 25.535 | 3.413 | 1.979 | 1.527 | 3.894 | 2.86 | 0.435 | 0 |
| Operating Expenses
| 155.542 | 155.121 | 128.244 | 111.69 | 39.575 | 15.978 | 15.955 | 12.226 | 11.917 | 5.397 | 0 |
| Operating Income
| -2.89 | -2.403 | -5.322 | -3.437 | 13.986 | -5.783 | -8.906 | -7.836 | -11.308 | -5.032 | 0 |
| Operating Income Ratio
| -0.009 | -0.008 | -0.022 | -0.017 | 0.295 | -0.463 | -1.032 | -1.319 | -10.905 | -13.774 | 0 |
| Total Other Income Expenses Net
| -19.098 | -2.916 | 19.522 | 62.741 | 39.665 | 35.247 | 30.105 | 31.309 | 48.324 | 136.086 | 0 |
| Income Before Tax
| -21.988 | -43.96 | 6.69 | 32.085 | 22.782 | 29.464 | 21.199 | 23.473 | 37.016 | 131.054 | 0 |
| Income Before Tax Ratio
| -0.067 | -0.15 | 0.027 | 0.161 | 0.48 | 2.357 | 2.455 | 3.952 | 35.695 | 358.734 | 0 |
| Income Tax Expense
| -5.153 | -14.068 | -8.985 | 0.325 | 4.749 | 5.385 | 3.955 | 4.913 | 2.849 | 5.195 | 0 |
| Net Income
| -16.835 | -29.892 | 15.675 | 31.76 | 14.517 | 24.079 | 17.244 | 18.56 | 34.167 | 125.859 | 0 |
| Net Income Ratio
| -0.051 | -0.102 | 0.064 | 0.159 | 0.306 | 1.926 | 1.997 | 3.125 | 32.948 | 344.514 | 0 |
| EPS
| -0.16 | -0.26 | 0.13 | 0.24 | 0.1 | 0.17 | 0.12 | 0.15 | 0.36 | 2.2 | 0 |
| EPS Diluted
| -0.16 | -0.26 | 0.13 | 0.24 | 0.1 | 0.17 | 0.12 | 0.15 | 0.35 | 2.2 | 0 |
| EBITDA
| 40.897 | 25.261 | 42.593 | 67.558 | 27.16 | -3.851 | -7.277 | -7.399 | -11.184 | 131.162 | 0 |
| EBITDA Ratio
| 0.125 | 0.205 | 0.175 | 0.144 | 0.385 | -1.25 | -1.008 | -1.281 | 10.944 | -1.674 | 0 |